← All tickers

Is PALI Worth Buying in 2026?

Palisade Bio, Inc. Common Stock

STOCK BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Updated 2026-04-19

Here’s whether Palisade Bio, Inc. Common Stock (PALI) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+4.06% over 10 days); RSI 65 — healthy momentum range; strong 1-year return of +242.7%; 3-month momentum positive (+44.6%). Currently 9.1% off its 52-week high. Score: +7/7.

Ready to act on this? 📈 Trade on Webull

PALI is in a confirmed uptrend, trading above both its 50-day ($1.86) and 200-day ($1.54) moving averages. An RSI of 64.7 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +242.7% compares to +35.1% for SPY (beat the market by 207.6%).

$10,000 invested 1 year ago → $34,271 today
vs. S&P 500 (SPY) — same period beat market by 207.6%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✓Above 200-day MA ($1.54)
✓Above 50-day MA ($1.86)
✓RSI(14) neutral zone (30–70) — currently 64.7
✓Positive return (+242.7%)
✓Within 10% of period high (−9.1%)
Period Range $2.40
$0.53 $2.64
RSI (14) 64.7
0 · OversoldOverbought · 100

Key Metrics

Price$2.40
Period Return+242.7%
Period High$2.64
Period Low$0.53
Drawdown−9.1%
MA-50$1.86
MA-200$1.54
RSI (14)64.7
Avg Volume (30d)4.1M
vs. SPYbeat by 207.6%
Return Rank#81 of 996

Trade PALI

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers